QuVa Pharma Secures National Drug Diversion Software Agreement with Premier
QuVa Pharma has been awarded a national group purchasing agreement with Premier, Inc. for its Drug Diversion Software Solutions, effective May 1, 2026. The deal enables Premier members to access pre-negotiated pricing and terms for QuVa's BrightStream platform, which supports controlled substance oversight and compliance.